Anti-(homo Sapiens Erbb2 (epidermal Growth Factor Receptor 2
Anti-(homo Sapiens Erbb2 (epidermal Growth Factor Receptor 2 Uses, Dosage, Side Effects, Food Interaction and all others data.
Anti-(homo Sapiens Erbb2 (epidermal Growth Factor Receptor 2 is under investigation in clinical trial NCT03262935 (SYD985 vs. Physician's Choice in Participants With Her2-positive Locally Advanced or Metastatic Breast Cancer).
Trade Name | Anti-(homo Sapiens Erbb2 (epidermal Growth Factor Receptor 2 |
Generic | Trastuzumab duocarmazine |
Trastuzumab duocarmazine Other Names | Immunoglobulin g1-kappa, anti-(homo sapiens erbb2 (epidermal growth factor receptor 2, receptor tyrosineprotein kinase erbb-2, egfr2, her2, her-2, p185cerbb2, neu, cd340)), humanized monoclonal antibody conjugated to the pro-drug seco-duocarmycinhydroxyb, Trastuzumab duocarmazine |
Type | |
Groups | Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | September 19, 2023 at 7:00 am |
![Anti-(homo Sapiens Erbb2 (epidermal Growth Factor Receptor 2 Anti-(homo Sapiens Erbb2 (epidermal Growth Factor Receptor 2](https://www.medicinesfaq.com/media/png/anti-homo-sapiens-erbb2-epidermal-growth-factor-receptor-2.png)
Innovators Monograph
You find simplified version here Anti-(homo Sapiens Erbb2 (epidermal Growth Factor Receptor 2